MRNA-5671

mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna. It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene. It is currently being evaluated for the treatment of either non-small cell lung cancer, colorectal cancers with microsatellite instability, or pancreatic adenocarcinoma, all with confirmed KRAS driver mutations. In 2021 Merck dropped the trial, and clinicaltrials.gov study NCT03948763 ended 2022-08-25. As of May 2024, no further progress on this vaccine has been announced.